Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics, Inc. filed a current report disclosing that it has announced its financial results for the quarter ended June 30, 2025. The company released these quarterly results through a press release dated August 8, 2025, which is included as Exhibit 99.1. This press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
Akero Therapeutics (AKRO) Q2 2025 10-Q highlights: The clinical-stage biotech remains pre-revenue and focused on its FGF21 analog efruxifermin (EFX). Operating expenses rose 23% YoY to $80.9 m as Phase 3 SYNCHRONY trials (≈3,500 pts, three global studies) ramped, driving a quarterly net loss of $70.5 m (-$0.86/sh) versus $56.0 m (-$0.81/sh) a year ago. Six-month loss totalled $141.2 m, up 29%.
Balance sheet strengthened by a January 2025 follow-on offering (6.4 m shares & 2.0 m pre-funded warrants) and ATM sales, adding ~$389 m net. Cash, cash equivalents and marketable securities reached $1.09 b (vs $0.83 b YE-24), offsetting a $115.9 m operating cash burn YTD and covering the $35.7 m Hercules term loan (interest-only until Jan-26). Management projects ≥12 months liquidity.
Key takeaways for investors: 1) Ample capital should fund completion of Phase 3, but ongoing R&D spend (~$69 m/qtr) will keep losses high. 2) Share dilution lifted WAVG shares 18% YoY to 81.7 m; additional ATM capacity of $262 m remains. 3) Investment thesis hinges on EFX clinical success; no alternative revenue sources exist. 4) Standard biotech risks—trial delays, manufacturing, competition and regulatory—are detailed in Risk Factors.
Akero Therapeutics (AKRO) – Form 4 insider transaction
President & CEO Andrew Cheng reported two open-market sales on 10 July 2025 executed under a previously adopted Rule 10b5-1 trading plan dated 16 Aug 2024.
- 14,686 shares sold at a weighted-average price of $50.57.
- 15,314 shares sold at a weighted-average price of $51.732.
- Total shares sold: 30,000; estimated gross proceeds ≈ $1.53 million based on disclosed averages.
- Post-sale direct holdings: 520,757 common shares (down from 550,757), indicating the CEO retains roughly 94% of his prior stake.
No derivative securities were involved. The filing notes that detailed trade-by-trade pricing is available upon request.
While insider sales can signal caution, the modest size (about 5.5 % of Cheng’s holdings) and the existence of a pre-arranged plan reduce potential negative interpretation. There are no indications of material changes to Akero’s operations or outlook within this filing.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
